Niche Focus Antisoma specializes in developing novel cancer treatments, indicating an opportunity to offer specialized solutions or partnerships in oncology research, drug development, and clinical testing support.
Early-Stage Development The company's strategy of acquiring promising early-stage drug candidates suggests potential for collaboration on clinical trial services, research tools, and early-phase development technologies.
Growth Potential With revenues ranging from $1M to $10M and a small team of 11-50 employees, Antisoma is positioned as a growing biotech firm, ideal for proposal of scalable solutions in biotech R&D and lab infrastructure.
Market Positioning Compared to larger competitors, Antisoma’s size and focus on innovative cancer drugs present opportunities to offer niche expertise, partner for advanced research platforms, or supply cutting-edge biotech tools.
Location Advantage Based in London, a global biotech hub, Antisoma can benefit from access to a vibrant research ecosystem, fostering opportunities for local partnerships, research collaborations, and industry networking.
$50M$100M
$100M$250M
$1B$10B
$50M$100M
$50M$100M| Antisoma Email Formats | Percentage |
| First.Last@antisoma.com | 50% |
| First.Last@antisoma.com | 50% |
Biotechnology ResearchEngland, United Kingdom11-50 Employees
Antisoma is a biotechnology company specialising in the development of novel drugs for the treatment of cancer. Our strategy is to acquire promising early-stage drug candidates from academic and commercial institutions around the world, to manage the development of these drugs through preclinical testing and clinical trials, and to bring them to the market
Company Overview
Funding & FinancialsAntisoma's revenue is estimated to be in the range of $1M$10M
Funding & FinancialsAntisoma's revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com